TABLE 2.
Contraceptive use and prevalence of female sexual dysfunction.
| Variable | n with FSD | Total eligible | Prevalence of FSD (%) |
|---|---|---|---|
| All study participants | 219 | 566 | 38.7 |
| Participants on hormonal contraceptives | 121 | 235 | 51.5 |
| Implants | 44 | 70 | 62.9 |
| Oral contraceptive pill | 42 | 74 | 56.8 |
| Injectable | 16 | 34 | 47.1 |
| Hormonal coil | 15 | 39 | 38.5 |
| Transdermal patches | 7 | 24 | 29.2 |
| Vaginal rings | 1 | 1 | 100.0 |
| Participants on non-hormonal contraceptives | 98 | 331 | 29.6 |
| Male and female condoms | 42 | 119 | 35.3 |
| Natural methods | 42 | 97 | 35.3 |
| Non-hormonal coil | 19 | 68 | 27.9 |
| Tubal ligation | 8 | 31 | 25.8 |
| Vaginal douching | 0 | 1 | 0.0 |
| Spermicides | 0 | 1 | 0.0 |
FSD, female sexual dysfunction.